These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 35933930)

  • 1. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
    Di M; Huntington SF; Olszewski AJ
    Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line treatment of diffuse large B-cell lymphoma: Evolution of options.
    Fabbri N; Mussetti A; Sureda A
    Semin Hematol; 2023 Nov; 60(5):305-312. PubMed ID: 38342663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
    Amaya ML; Jimeno A; Kamdar M
    Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse large B-cell lymphoma: new targets and novel therapies.
    Cheson BD; Nowakowski G; Salles G
    Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
    Malecek MK; Watkins MP; Bartlett NL
    Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
    Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
    J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
    N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
    Varma G; Wang J; Diefenbach C
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Gordon MJ; Sureda A; Westin JR
    Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Nedved A; Maddocks K; Nowakowski GS
    Oncologist; 2023 Mar; 28(3):199-207. PubMed ID: 36648324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
    Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
    Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
    Lu Q; Huang H; Tang S; Wang Y; Yang DH
    Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.